ESTRO 2023 - Abstract Book

S333

Sunday 14 May 2023

ESTRO 2023

imaging and cystoscopy determined recurrence, progression-free survival (PFS), and cancer-specific survival (CSS). Subgroup differences were compared using T and χ 2 tests. Survival was analysed by Kaplan-Meier, log-rank, and multivariate Cox proportional hazard regression. Statistical analysis was conducted using R (R Core Team (2022)). Results Of the 443 patients analysed, 210 were treated with BCON; 233 were treated with GemX. The median follow-up was 32m (6-66). Patient characteristics are shown in Table 1 . BCON patients were older, significantly less fit, received less neoadjuvant chemotherapy, and had more non-TCC cancers and less T3 staging. Treatment completion rates were 96% for GemX and 95% for BCON. There were significantly more hospitalisations (4%) and acute grade 3 toxicities (19%) after GemX radiotherapy (p<0.001) but there was no difference in late toxicity (p=0.354). 3-month cystoscopy post radiotherapy demonstrated complete response in 92% (151/164) of BCON and 90% (187/208) of GemX. Overall, 107 (24%) progressed after BCON and 116 (26%) following GemX. Patterns of recurrences are demonstrated in Table 1 and did not differ significantly between BCON and GemX. 3-year PFS was 45% for BCON and 49% for GemX (HR 0.77, 95%CI (0.59-1.0, p=0.052); 3-year BCON CSS was 52% and 70% for GemX (HR 0.53, 95%CI 0.38-0.73, p<0.001) as shown in Figure 1 . When adjusted for clinical factors (neoadjuvant chemotherapy, gender, age, performance status, T-stage, ACE-27, and carcinoma in-situ) in a multivariate Cox model, both PFS (HR 0.70 95%CI 0.50-0.96, p=0.027) and CSS (HR 0.56, 95%CI 0.38-0.82, p=0.0026) were significant in favour of GemX. Conclusion Our real-world data is comparable to published BCON and GemX outcomes and both methods of radiosensitisation have acceptable toxicity and high treatment completion rates. Patterns of recurrence were similar regardless of radiosensitisation. CSS was superior in GemX patients, but differences in outcomes for GemX and BCON are likely explained by differing use of neoadjuvant chemotherapy and patient factors. Given that this is non-randomised data, direct comparisons of both treatments should be treated with caution.